XOMA - XOMA Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.51
-0.36 (-2.42%)
As of 11:30AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close14.87
Open14.88
Bid14.42 x 1100
Ask14.52 x 800
Day's Range14.21 - 14.90
52 Week Range11.88 - 37.25
Volume36,055
Avg. Volume96,155
Market Cap121.816M
Beta (3Y Monthly)3.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Xoma: 3Q Earnings Snapshot

    On a per-share basis, the Emeryville, California-based company said it had a loss of 55 cents. The drug developer posted revenue of $896,000 in the period. Xoma shares have declined 65 percent since the ...

  • Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?
    Zackslast month

    Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important
    Simply Wall St.3 months ago

    The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important

    A look at the shareholders of XOMA Corporation (NASDAQ:XOMA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...

  • Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
    Zacks4 months ago

    Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Xoma: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Associated Press7 months ago

    Xoma: 1Q Earnings Snapshot

    The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Associated Press9 months ago

    Xoma reports 4Q loss

    The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...

  • AbbVie Presents New Data on Upadacitinib for Crohn's Disease
    Zacks10 months ago

    AbbVie Presents New Data on Upadacitinib for Crohn's Disease

    AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

  • FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
    Zacks10 months ago

    FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

    FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

  • AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
    Zacks10 months ago

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

  • Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
    Zacks10 months ago

    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

  • Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
    Zacks10 months ago

    Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

    Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

  • Pfizer Files for Xtandi in Early Stage Prostate Cancer
    Zacks10 months ago

    Pfizer Files for Xtandi in Early Stage Prostate Cancer

    Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

  • Puma, CANbridge Team Up to Commercialize Nerlynx in China
    Zacks10 months ago

    Puma, CANbridge Team Up to Commercialize Nerlynx in China

    Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.

  • Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
    Zacks10 months ago

    Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review

    Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.

  • Puma & Medison Team Up to Commercialize Nerlynx in Israel
    Zacks10 months ago

    Puma & Medison Team Up to Commercialize Nerlynx in Israel

    Puma (PBYI) and Medison enters into a licensing deal to commercialize Puma's breast cancer treatment drug Nerlynx in Israel.

  • Theravance's NDA for COPD Candidate Gets FDA Acceptance
    Zacks10 months ago

    Theravance's NDA for COPD Candidate Gets FDA Acceptance

    The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.

  • Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion
    Zacks10 months ago

    Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

    The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

  • Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
    Zacks10 months ago

    Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

    Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

  • Shire Gets FDA Nod for Cinryze Tech Transfer to New Site
    Zacks10 months ago

    Shire Gets FDA Nod for Cinryze Tech Transfer to New Site

    Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.

  • EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
    Zacks11 months ago

    EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down

    Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.

  • 3 Pharma and Biotech Stocks to Watch Out for in 2018
    InvestorPlace11 months ago

    3 Pharma and Biotech Stocks to Watch Out for in 2018

    2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. There was a significant surge in FDA approvals, investors appeared more comfortable with the drug pricing controversy and innovation won the day with the FDA granting approval to gene therapies for cancer as well as a rare form of blindness. As we start the New Year, here is a look at three drug stocks that look well-positioned for 2018 and are witnessing upward estimate revisions and have a favorable Zacks Rank – Zacks Rank #1 (Strong Buy) or #2 (Buy).

  • Anthera's Sollpura Strong on Positive Futility in Phase III
    Zacks11 months ago

    Anthera's Sollpura Strong on Positive Futility in Phase III

    Anthera (ANTH) posts positive results from the second interim futility analysis of Sollpura for EPI. Top-line data from the study is expected in the first quarter of 2018.